新药周观点：24Q3创新药板块持仓环比增长，机构关注度不断提升中

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the biotech innovation drug sector [2]. Core Insights - The report highlights a significant increase in institutional interest in the biotech innovation drug sector, with a 45.1% quarter-over-quarter growth in the total market value of heavy holdings by all funds, reaching 37.069 billion yuan [3]. - The report notes that the proportion of heavy holdings in biotech innovation drugs relative to the overall market increased by 0.19 percentage points to 1.08%, while the proportion relative to the pharmaceutical industry rose by 2.17 percentage points to 11.39% [3]. - The report indicates that there is still room for growth in institutional holdings of biotech innovation drugs, as the proportion of heavy holdings relative to the total market capitalization decreased by 0.22 percentage points to 4.91% [3]. Weekly New Drug Market Review - From October 28 to November 2, 2024, the top five companies in the new drug sector by growth were Rongchang Biotech (21.35%), Kexi Pharmaceutical (15.42%), Qianyan Biotech (8.35%), Beihai Kangcheng (7.88%), and Junsheng Tai Pharmaceutical (6.25%). The top five companies by decline were Innovent Biologics (-20.79%), Hansoh Pharmaceutical (-14.02%), WuXi AppTec (-13.94%), Shouyao Holdings (-13.37%), and CSPC Pharmaceutical Group (-13.13%) [2][21]. New Drug Approval & Acceptance - In the past week, one new drug or new indication was approved for market launch, 32 new drugs were approved for IND, 40 new drugs had IND accepted, and five new drugs had NDA accepted [4][32]. Key Focus in Domestic New Drug Industry - Key highlights include the approval of Shugli monoclonal antibody for first-line treatment of metastatic non-small cell lung cancer, the announcement of KarXT's phase III bridging study results for schizophrenia treatment, and the acceptance of a new indication application for a monoclonal antibody by Kelong Biotech [5][10][11]. Key Focus in Overseas New Drug Industry - Notable developments include a collaboration agreement worth approximately $1.5 billion between AbbVie and Evolvelmmune Therapeutics for developing multi-specific biologics targeting multiple oncology pathways, and positive results from Roche's trial of an antibody for treating mild to moderate Alzheimer's disease [6][11]. Heavy Holdings Analysis - The report identifies that the top ten companies with heavy holdings in biotech innovation drugs include Innovent Biologics, BeiGene (A-shares), Baillie Gifford, Kanyin Biotech, Zai Lab, BeiGene (H-shares), Kelun Biotech, Hutchison China MediTech, Rongchang Biotech (A-shares), and Nocera Health. The companies with the largest increases in heavy holdings relative to total market capitalization were Baillie Gifford (+6.6 percentage points), Zai Lab (+6.4 percentage points), and Hutchison China MediTech (+5.7 percentage points) [3][30].